Successful treatment of autoimmune thrombocytopenic purpura with rituximab in a dialysis patient with systemic lupus erythematosus

International Immunopharmacology

Volumn 10, Issue 5, 2010, Pages 632-634

  Lee, Shen Yang ^a   Hsu, Po Yaur ^a   Juan, Kuo Chang ^a   Chang, Hung ^a   Huang, Wen Hung ^a   Lai, Ping Chin ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Autoimmune thrombocytopenic purpura; Dialysis; Rituximab; Systemic lupus erythematosus

Indexed keywords

METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CASE REPORT; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG PULSE THERAPY; DRUG RESPONSE; DRUG SAFETY; ECCHYMOSIS; FEMALE; GINGIVA BLEEDING; HEMODIALYSIS PATIENT; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; PLASMAPHERESIS; PRIORITY JOURNAL; PURPURA; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE COUNT; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; B-LYMPHOCYTES; BLOOD PLATELETS; DRUG RESISTANCE; FEMALE; HUMANS; IMMUNOTHERAPY; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE DEPLETION; MIDDLE AGED; PLATELET COUNT; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RENAL DIALYSIS; STEROIDS;

EID: 77950519177     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2010.02.007     Document Type: Article

References (12)

1. Bussel J. Treatment of immune thrombocytopenic purpura in adults. Semin Hematol 43 Suppl-10 (2006)
2. Garcia-Carrasco M., Jimenez-Hernandez M., Escarcega R.O., Mendoza-Pinto C., Galarza-Maldonado C., Sandoval-Cruz M., et al. Use of rituximab in patients with systemic lupus erythematosus: an update. Autoimmun Rev 8 (2009) 343-348
3. Krane N.K., Burjak K., Archie M., and O'donovan R. Persistent lupus activity in end-stage renal disease. Am J Kidney Dis 33 (1999) 872-879
4. Dierickx D., De R.A., Vanderschueren S., and Delannoy A. New treatment options for immune-mediated hematological disorders. Eur J Int Med 19 (2008) 579-586
5. Salama A.D., and Pusey C.D. Drug insight: rituximab in renal disease and transplantation. Nat Clin Pract Nephrol 2 (2006) 221-230
6. Arnold D.M., Dentali F., Crowther M.A., Meyer R.M., Cook R.J., Sigouin C., et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 146 (2007) 25-33
7. Lindholm C., Borjesson-Asp K., Zendjanchi K., Sundqvist A.C., Tarkowski A., and Bokarewa M. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. J Rheumatol 35 (2008) 826-833
8. Lu T.Y., Ng K.P., Cambridge G., Leandro M.J., Edwards J.C., Ehrenstein M., et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum 61 (2009) 482-487
9. Ramos-Casals M., Soto M.J., Cuadrado M.J., and Khamashta M.A. Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus 18 (2009) 767-776
10. Merrill J.T., Neuwelt C.M., Wallace D.J., Shanahan J.C., Latinis K.M., Oates J.C., et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 28 62 (2009) 222-233
11. Ng K.P., Cambridge G., Leandro M.J., Edwards J.C., Ehrenstein M., and Isenberg D.A. B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann Rheum Dis 66 (2007) 1259-1262
12. Carson K.R., Evens A.M., Richey E.A., Habermann T.M., Focosi D., Seymour J.F., et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 113 (2009) 4834-4840